Fulcrum Therapeutics achieved what the company is calling a clinical first. Data from a Phase IIb study showed that using losmapimod to treat facioscapulohumeral muscular dystrophy (FSHD) slowed the progression of the disease and demonstrated improved function in patients.
Eli Lilly will apply for U.S. health regulator’s accelerated approval during 2021 for the company’s experimental Alzheimer’s drug, weeks after Biogen Inc.’s controversial drug for the disease was approved.
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.
Data from clinical trials of three experimental Alzheimer’s disease drugs expected to start emerging during 2022 could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc. treatment without clear evidence that Aduhelm works.
Topline results from the Phase III TULIP study show an antibody-drug conjugate (ADC) from the Netherlands-based Byondis B.V. significantly prolonged progression-free survival (PFS) in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).
As the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting presents many clinical trial updates, there appears to be a theme: access to drugs and pricing.
Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental tumor-targeting radiation therapy from Swiss drugmaker Novartis, data released on June 3 showed.
Migraine headaches can be reduced in frequency and severity by atopant, an oral therapy developed by AbbVie, according to data presented at the 2021 American Headache Society’s (AHS) Annual Scientific Meeting.
On the cusp of the 2021 American Society of Clinical Oncology meeting, more companies are announcing data presentations that will be made over the four-day conference as BioSpace continues to take a look at some of the data that will be shared.
Two Covid-19 vaccines from China’s Sinopharm showed more than 70 percent efficacy against symptomatic cases, but it remains unclear how much protection they provide against severe or asymptomatic cases, according to the first detailed result of a large late-stage study published to the public.
© AbbVie Inc. All rights reserved.